We're ScreenPoint Medical

We are focused on helping to improve breast cancer survival rates by detecting cancers earlier so that treatment can be more effective and less invasive.

Screenpoint logo

Improve patient outcomes

We are working with breast clinicians to continually improve the clinically proven deep learning algorithms in Transpara™. We are committed to further improve accuracy, consistency and reduce unnecessary recalls, a common cause of anxiety for women undergoing mammography.

Deep learning
From the leaders in development of deep learning Artificial Intelligence (AI) for mammography and breast imaging picture

40 years experience

From the leaders in development of deep learning Artificial Intelligence (AI) for mammography and breast imaging

Our history

ScreenPoint Medical was founded in 2014 by Professor Nico Karssemeijer and Professor Sir Michael Brady, world leading experts in quantitative breast image analysis and computer aided detection.

Read more

Our history

ScreenPoint Medical was founded in 2014 by Professor Nico Karssemeijer and Professor Sir Michael Brady, world leading experts in quantitative breast image analysis and computer aided detection.

They have led research projects in the field for over twenty years and have made important contributions to leading breast imaging products. 

Prof Karssemeijer says, “I started ScreenPoint Medical because I wanted my academic work to have a greater impact beyond the publication of scientific papers. I knew our work held out the promise to ultimately improve breast cancer survival rates and recognised the huge potential of my university team to develop a really outstanding product. By using the technological advances of Deep Learning Artificial Intelligence, we have overtaken current CAD systems to produce faster and more accurate results.”



Our technology

The resulting product, Transpara, has featured in multiple peer-reviewed publications that show it enables significant clinical improvements to the timely diagnosis of breast cancer.

Read more

Our technology

The resulting product, Transpara, has featured in multiple peer-reviewed publications that show it enables significant clinical improvements to the timely diagnosis of breast cancer.

“Transpara is now being used by radiologists in clinical practice, but this is only the beginning! We are constantly innovating and we will continue to help doctors to achieve higher breast cancer survival rates and at the same time, minimise patient distress and the cost of unnecessary treatments.”

“But we always remember that our excellence in innovation must be matched by the way we run our business. We are lean, focused on producing optimum results with cost savings passed on to our customers.”

Co-Founder of ScreenPoint Medical, Sir Michael Brady, was known internationally for his ground-breaking work in robotic image analysis at the University of Oxford but the death of his mother in law from breast cancer, caused him to change direction:

“I wanted to understand why the medical profession wasn’t able to do a better job of detecting breast cancers at an earlier stage when they were more treatable.  So I decided to move away from robotics and concentrate on the analysis of breast scans.’

My colleagues and I developed a mathematical model of the passage of X-rays through female breast tissue, a fundamental step towards developing a system able to recognise potential tumours.

I met Nico Karssemeijer from Nijmegen University in 2000 when he was giving a keynote lecture on parallel research.

Both of us wanted to help radiologists identify potential cancers faster and at an earlier stage and to increase the chances of more women surviving breast cancer.

In 2014 we started ScreenPoint Medical.  We built a superb team of scientists to develop a unique system, Transpara, a blend of classic physics and deep learning artificial intelligence, presented as a decision support tool to increase efficiency.

There are fewer and fewer radiologists specialising in reading mammograms at a time when breast cancer incidence is increasing worldwide.

ScreenPoint are the only people that combine deep understanding of the physics, knowledge of clinical workflow and deep learning AI techniques to improve accuracy and speed of detection. Transpara is the world leader!”



Our Dedicated Team

 picture

Nico Karssemeijer

CEO

View Biog
 picture

Sir Michael Brady

Chairman

View Biog
 picture

Carl Evertsz

Non-Executive Director

View Biog
 picture

Guido Du Pree

Non-Executive Director

View Biog
 picture

Anirudha Dambal

Non-Executive Director

View Biog
 picture

Pieter Kroese

COO

View Biog
 picture

Albert Gubern-Mérida

Head of R&D

View Biog
 picture

Nico Karssemeijer

CEO

Professor Nico Karssemeijer is a leading scientist in breast cancer imaging and has been one of the pioneers of computer-aided detection, playing a key role in its development and adoptation in breast cancer screening. He was closely involved in the development of the R2 ImageChecker, the first mammography CAD product. He also played an important role in implementing digital mammography in the European screening programs, by initiating and leading EU funded projects in which breast screening workstations were developed that are marketed today by major vendors. He is a Professor in the Department of Radiology, Radboud University, Nijmegen, The Netherlands, and he is co-founder of Matakina Ltd and of QView Medical Inc.

 picture

Sir Michael Brady

Chairman

Professor Sir Michael Brady FRS FMedSci FREng is a world leading scientist in computer vision, robotics, and medical image analysis.  He co-authored Mammographic Image Analysis (Kluwer 1999) with Ralph Highnam; the ideas introduced in this monograph – together with some later innovative developments by Nico Karssemeijer and colleagues – provided the basis for Volpara density.  As well, Brady has co-founded and steered several small high-growth technology companies to success.  In addition to Matakina, he is a Founder Director of: Perspectum Diagnostics, Mirada Medical, and Guidance Navigation; as well as being Chairman of:  Acuitas Medical, IRISS Medical, Colwiz,  and was until recently Deputy Chairman of Oxford Instruments plc.

 picture

Carl Evertsz

Non-Executive Director

Dr. Carl Evertsz has extensive experience founding, leading, and growing innovative medical imaging companies. He actively led international business-, corporate- and R&D- developments, including an IPO, M&A and technology acquisitions. He also spearheaded the development and commercialization of multi-modality breast reading solutions, which significantly contributed to creating today’s de facto industry standards. Until 2012 Carl served as CEO of MeVis Medical Solutions AG, a publicly traded developer and provider of medical imaging software that he co-founded, and of MeVis BreastCare. He is managing director and owner of Pandushi, a private asset management and investment firm and serves in the supervisory board of Medis Medical Imaging Systems B.V.

 picture

Guido Du Pree

Non-Executive Director

Guido du Pree, M.Sc. has many years of experience in venturing, (digital) innovation and revenue growth in Medical Imaging, IVD, Healthcare Informatics and Genomics companies. He co-founded, built and managed the Philips Digital Pathology venture. Currently the venture is one of the spearheads in Philips Health growth ambitions with tens of millions of revenue and more than 300 people on the payroll. Two years ago, Guido founded an online market place for innovative Molecular/Genetic Diagnostic tests to make these tests easy available to cancer patients and their doctors. The first part of his career he spent in strategy consulting, M&A and fund raising for start-ups.

 picture

Anirudha Dambal

Non-Executive Director

Anirudha has strong cross-functional expertise across general management, strategy, product & innovation management, and sales operations addressing customers across the world. In his function as vice president of New X-ray Markets at Siemens Healthineers, he is responsible for identifying and bringing new business opportunities in the X-ray products business line to the market. In his previous role, he was the head of the global value segment X-ray products where he drove the definition and development of a new mobile C-arm platform. He has also served as the head of CRM and sales analytics and as business manager for South Asia in prior positions. As a non-executive director at ScreenPoint Medical, he is jointly working towards improved breast cancer diagnosis using artificial intelligence.

 picture

Pieter Kroese

COO

Pieter Kroese has extensive international experience in general, commercial and financial management, and has always been intensively involved in strategy development. He has a background in various industries, leading organisations of up to 400 people. He also developed hands-on entrepreneurial experience as co-founder of a technical startup company. During the last 7 years, Pieter has primarily been working with software development companies. He joined ScreenPoint in 2018 and is responsible for all business activities, driving the commercial focus and growth of the company, as well as assuming responsibility for operations and finance.

 picture

Albert Gubern-Mérida

Head of R&D

Dr. Gubern-Mérida obtained his joint Ph.D. degree in the field of medical imaging at the Diagnostic Image Analysis Group (DIAG) of the Radboud University Medical Center (Nijmegen, the Netherlands) and the University of Girona (Girona, Spain). His research focused on automated analysis of breast MRI, by developing image analysis and machine learning algorithms for breast cancer detection. As a post-doctoral researcher at DIAG, he expanded his research interest to other breast imaging modalities (mammography, digital breast tomosynthesis, and automated 3D breast ultrasound). In 2016, Dr. Gubern-Mérida joined ScreenPoint Medical, where he is currently the Head of Research and Development, leading the continuous evolution of the AI technology within the company.

Join our team

ScreenPoint Medical is a fast growing company that develops and markets AI products and services to improve early detection of breast cancer. We always welcome applications from strong candidates who share our mission and have expertise in our field. Feel free to send your resume and motivation letter to us.

Apply here

Coverage

Significantly better breast AI picture

Significantly better breast AI

ScreenPoint has assembled a world-class team of researchers and engineers with extensive experience in breast imaging, machine learning, algorithm development, and clinical research. The team is highly motivated to develop technology that can make a difference in the early detection of breast cancer. Close collaboration with radiologists ensures that products meet clinical needs and fit in the workflow of a busy breast imaging practice. Our research and development efforts are aimed at achieving superior performance of detection algorithms and understanding the impact of Transpara in all types of clinical practice

Read publication

News

Article


The latest AI breast cancer identification system, Transpara™ 1.6 will be showcased at RSNA 2019

The most advanced version of Transpara™ from ScreenPoint Medical unleashes the power from 2D into 3D mammography: Performance is better,

Read more
This is alt text

Article


Transpara™ by ScreenPoint Medical to showcase new medical education program to demonstrate real life use of breast AI

ScreenPoint Medical launches its new medical education program with a series of workshops entitled, “The Transpara experience – true multi-vendor,

Read more
This is alt text

Article


Volpara signs distribution agreement to sell Transpara™, Screenpoint Medical’s AI solution for breast cancer detection

WELLINGTON, New Zealand, July 23, 2019 /PRNewswire/ — Volpara Solutions and ScreenPoint Medical BV today announced signature of an agreement under which Volpara will sell ScreenPoint’s Transpara™ products

Read more
Lady alt text

Article


Affidea partners to increase diagnostic accuracy

Affidea and ScreenPoint Medical announced a strategic partnership to streamline and improve the clinical performance of screening mammography and drive

Read more
Lady alt text

Publication


Transpara™ AI software equals radiologists in study published in the Journal of the National Cancer Institute

Deep learning software Transpara is shown to be robust and reliable in the largest AI study with screening mammograms to

Read more
This is alt text

Article


ScreenPoint Medical – winner of the best new radiology vendor in the inaugural EuroMinnie awards 2019

ScreenPoint Medical is honoured to be winner of the Best New Radiology Vendor in the inaugural EuroMinnie awards 2019. According

Read more